US equities |
AAPL $338.32 ▲+0.00% MU $833.59 ▲+0.00% SNDK $1,075.08 ▲+0.00% GOOGL $278.99 ▲+0.00% PLTR $178.34 ▲+0.00% NVDA $202.06 ▲+0.00% INTC $59.97 ▲+0.00% SPCX $136.37 ▲+0.00%
FinancialContent

Axogen, Inc. - Common Stock (NQ:AXGN)

49.85 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axogen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
AxoGen Q3 Earnings Call Highlights ↗
AxoGen (NASDAQ:AXGN) reported third-quarter revenue growth of 26.2% as demand for its nerve-repair products increased across its breast, extremities, oral and maxillofacial, and head-and-neck markets.... 
Via MarketBeat
Topics Earnings
Top US Stock Movers in Today's Session ↗
Via Chartmill
News headline image
Axogen (AXGN) Q3 2026 Earnings Call Transcript ↗
Breast segment surged 60% while BioCircuit acquisition expands nerve repair market reach. 
Via The Motley Fool
Topics Earnings
Axogen (NASDAQ:AXGN) Stock Jumps on Q3 Earnings Beat and Strong 2026 Revenue Guidance ↗
Via Chartmill
Topics Earnings
Axogen (NASDAQ:AXGN) Shares Slide After Q2 Earnings Miss Overshadows Revenue Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
Axogen Inc. (NASDAQ:AXGN) Achieves a Perfect Technical Score and Strong Fundamental Growth ↗
Via Chartmill
Axogen Inc (NASDAQ:AXGN) Rallies on Q1 Revenue Beat and Raised 2026 Guidance ↗
Via Chartmill
US Top Movers: Biggest Gainers and Decliners in Today's Session ↗
Via Chartmill
Oct. 28 Gap Stocks: Double-Digit Gap-Up and Gap-Down Movers ↗
Via Chartmill
Premarket Movers for Oct. 28, 2026: Gainers and Losers ↗
Via Chartmill
News headline image
Axogen, Inc. Reports Third Quarter 2026 Financial Results
Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
From Axogen, Inc.
Via GlobeNewswire
News headline image
Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
From Wall Street Investor
Via GlobeNewswire
News headline image
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
From Axogen, Inc.
Via GlobeNewswire
News headline image
3 Emerging Biotech Stocks With Significant Upside Potential ↗
Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs. 
Via MarketBeat
Topics Intellectual Property
News headline image
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen (AXGN) Q2 2026 Earnings Call Transcript ↗
Breast segment revenue surged over 50% year over year, driving accelerated growth. 
Via The Motley Fool
Topics Earnings
News headline image
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
News Provided by Biotech Insider on behalf of Conexeu Sciences Inc. 
From Biotech Insider
Via GlobeNewswire
News headline image
AxoGen Q2 Earnings Call Highlights ↗
AxoGen (NASDAQ:AXGN) reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target... 
Via MarketBeat
Topics Earnings
News headline image
Axogen, Inc. Reports Second Quarter 2026 Financial Results
Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
From Axogen, Inc.
Via GlobeNewswire
News headline image
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
From Energy Metal News
Via GlobeNewswire
News headline image
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam ↗
AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are... 
Via MarketBeat
News headline image
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
From TELA Bio, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen (AXGN) Q3 2025 Earnings Transcript ↗
Axogen (AXGN) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Axogen (AXGN) Q1 2025 Earnings Transcript ↗
Axogen (AXGN) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Axogen, Inc. Reports First Quarter 2026 Financial Results
Raises Full Year Revenue Guidance to at Least 20% Growth or $270 million 
From Axogen, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >